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Abstract
Background: Regional contractile dysfunction is a frequent finding in hypertrophic cardiomyopathy (HCM). We
aimed to investigate the contribution of different tissue characteristics in HCM to regional contractile dysfunction.
Methods: We prospectively recruited 50 patients with HCM who underwent cardiovascular magnetic resonance
(CMR) studies at 3.0 T including cine imaging, T1 mapping and late gadolinium enhancement (LGE) imaging. For
each segment of the American Heart Association model segment thickness, native T1, extracellular volume (ECV),
presence of LGE and regional strain (by feature tracking and tissue tagging) were assessed. The relationship of
segmental function, hypertrophy and tissue characteristics were determined using a mixed effects model, with
random intercept for each patient.
Results: Individually segment thickness, native T1, ECV and the presence of LGE all had significant associations
with regional strain. The first multivariable model (segment thickness, LGE and ECV) demonstrated that all strain
parameters were associated with segment thickness (P < 0.001 for all) but not ECV. LGE (Beta 2.603, P = 0.024) had a
significant association with circumferential strain measured by tissue tagging.
In a second multivariable model (segment thickness, LGE and native T1) all strain parameters were associated with
both segment thickness (P < 0.001 for all) and native T1 (P < 0.001 for all) but not LGE.
Conclusion: Impairment of contractile function in HCM is predominantly associated with the degree of
hypertrophy and native T1 but not markers of extracellular fibrosis (ECV or LGE). These findings suggest that
impairment of contractility in HCM is mediated by mechanisms other than extracellular expansion that include
cellular changes in structure and function. The cellular mechanisms leading to increased native T1 and its
prognostic significance remain to be established.
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Background
Hypertrophic cardiomyopathy (HCM) is commonly de-
fined as a disease of hypertrophy of the left ventricle
(LV) in the absence of another cardiac or systemic cause
[1]. Various patterns of hypertrophy are recognised [2]
including widespread, asymmetric or eccentric myocar-
dial thickening although most patients have a significant
proportion of myocardium that is spared from overt
hypertrophy [3].
HCM is most commonly caused by mutation in genes
encoding proteins within the unit of myocardial contrac-
tion, the sarcomere [4]. The mechanisms that lead from
dysfunction of the sarcomere to overt hypertrophy are
complex and not as yet fully understood. Potential
mechanisms include impaired calcium cycling, intersti-
tial fibrosis, disturbed biomechanical stress sensing and
microvascular dysfunction [5].
Previous studies predominantly performed with echo-
cardiography speckle tracking have shown that there is
widespread variation in myocardial contractility through-
out the ventricle in HCM. Regional impairment of
contractility is predominantly related to the extent of
hypertrophy and presence of replacement fibrosis [6, 7].
Current guidelines therefore recommend that strain
imaging could be used to investigate unexplained left
ventricular hypertrophy that is not diagnostic of HCM
[1, 8]. Alternative methods to echocardiography for the
assessment of regional strain are cardiovascular mag-
netic resonance (CMR) tagging [9, 10] and post process-
ing feature tracking (FT) [11–13] which are both highly
reproducible and show good agreement.
Using CMR it is also possible to assess the tissue char-
acteristics of the HCM phenotype. After administration
of gadolinium based contrast agent, which is exclusively
extracellular, late gadolinium enhancement (LGE) im-
aging allows identification of areas of focal fibrosis.
Histological validation has suggested that the presence
of LGE in HCM reflects replacement fibrosis [14], which
is progressive over the course of the disease [15] and is
associated with an adverse prognosis [16, 17].
LGE is a qualitative technique relying upon contrast
between tissue with and without fibrosis, and is there-
fore of limited use in the detection of diffuse fibrosis.
For this purpose T1 mapping techniques are used that
give a quantitative pixel-wise map of myocardial T1
values. This can be performed without contrast (native
T1), or by measuring both pre and post contrast T1maps
to compute pixel-wise map of extracellular volume frac-
tion (ECV %) [18]. ECV has been validated in surgical
samples in HCM and has been shown to correspond to
the histologically measured extent of fibrosis [19, 20].
Native T1 is influenced by several factors including
extracellular space expansion (as is ECV) but also intra-
cellular iron, lipid and water content [21, 22]. Native T1
has also been shown to be elevated in HCM [23] and
both native T1 and ECV are elevated in genotype posi-
tive patients without overt hypertrophy [24, 25].
It is presently unknown which tissue characteristics
are associated with contractile dysfunction in HCM. We
therefore planned to assess native T1, ECV and LGE seg-
mentally and quantify their association with strain mea-
sured in the same segment. This would provide insight
into the pathological processes that lead to impaired
contractility in HCM.
Methods
Enrolment criteria
Fifty consecutive patients with HCM were prospectively re-
cruited from the local Inherited Cardiovascular Conditions
Service between August 2014 and August 2015 and healthy
controls (N = 30) were also recruited. The diagnosis of
HCM was made independently by clinicians in keeping
with current guidelines and based upon imaging including
CMR, ECG, exercise testing, family history and genetic
testing if possible [1, 8]. Exclusion criteria were previous
surgical myomectomy, previous septal ablation, atrial
fibrillation, previous myocardial infarction, uncontrolled
hypertension, permanent pacemaker, defibrillator or other
contraindication to CMR. Healthy controls had no existing
medical conditions and were not taking any regular medi-
cation were also recruited to establish the normal range of
ECV using the identical CMR protocol.
CMR protocol
All subjects underwent an identical CMR protocol
performed on a 3.0 Tesla Philips Achieva TX system
(Philips, Best, The Netherlands) equipped with a 32
channel cardiac phased array receiver coil. A full blood
count, including haematocrit was measured at the time
of intravenous cannulation. The cardiac long and short
axes were determined using standard scout views. Basal,
mid and apical pre-contrast (native) short axis T1 maps
were generated using a validated Modified Look Locker
Inversion (MOLLI) protocol [26] (ECG triggered 5b (3 s)
3b MOLLI scheme with voxel size of 1.98 x 1.98 mm2,
slice thickness 10 mm) and were planned using the 3 of
5 method [27]. Tissue tagging using a spatial modulation
of magnetization (SPAMM) pulse sequence (spatial reso-
lution 1.51x1.57x10mm3, tag separation 7 mm, ≥18
phases, typical TR/TE 5.8/3.5 ms, flip angle 10°, typical
temporal resolution 55 ms) was acquired in the same
three short axis slices in 34/50 patients. Left ventricular
volumes were obtained from cine imaging covering the
entire LV in the short axis: balanced steady state free
precession (SSFP), voxel size 1.2 x 1.2 mm2, slice thick-
ness 10 mm with no gap, 50 cardiac phases. Left atrial
(LA) volumes were obtained from cine imaging covering
the entire heart in the transverse axis: balanced SSFP,
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voxel size 1.2 x 1.2 mm2, slice thickness 6 mm with no
gap, 50 cardiac phases. 0.15 mmol/Kg Gadovist (Bayer
Schering) was delivered by power injector (Medrad Inc,
Warrendale, Pennsylvania, USA) as a single bolus via a
cannula placed in the ante-cubital fossa followed by 20 ml
saline flush. Typical parameters for LGE were TR/TE 3.5/
2.0 ms, flip angle 25°, acquired spatial resolution
1.54x1.76x10mm3 and performed in 10-12 short axis slices
with ≥3 long axis orientations and phase-swapped acquisi-
tions if indicated. Post contrast T1 mapping, using the
same 5b (3 s) 3b MOLLI scheme as for native T1 map-
ping, was carried out in the same three slices exactly
15 min following last contrast injection (as above).
CMR interpretation
Analysis was carried out using CVI42 (Circle Cardiovascular
Imaging Inc. Calgary, Canada) and inTag (v1.0, CREATIS
lab, Lyon, France) by two physicians blinded to clinical
data. LV mass, end diastolic volumes (EDV), end systolic
volume (ESV) and LV ejection fraction (EF) were mea-
sured from short axis cine images excluding papillary
muscles and trabeculations. Native and post contrast T1
relaxation time of myocardium and blood pool were
measured from the three scanner generated T1 maps by
contouring a region of interest in each segment of the 16
segment American Heart Association (AHA) model [28].
ECV was calculated from native and post contrast T1
times of myocardium and blood pool and haematocrit
as previously reported [19]. Segment thickness was
measured for each AHA segment from the identical
end-diastolic SSFP cine images corresponding to the T1
maps. Feature tracking analysis was carried out on the
same images by drawing endocardial and epicardial
contours and circumferential (Ecc-FT) and radial
(Err-FT) strain calculated for each AHA segment. The
reproducibility of Ecc-FT and Err-FT tested in 30 seg-
ments from 6 patients was good (intraobserver Ecc-FT
11.0%, Err-FT 7.7% and interobserver Ecc-FT 13.4%,
Err-FT 10.1%).
For tagging analysis endocardial and epicardial con-
tours were drawn on the short axis SPAMM sequences.
Peak circumferential strain was measured for each seg-
ment of the AHA model using inTag (v1.0, CREATIS
lab, Lyon, France). Strain was measured in the mid-
myocardial layer (by disregarding epicardial and endo-
cardial layers) which has previously been reported to be
the most reproducible [10].
Segments were defined as hypertrophied if the max-
imal thickness was ≥15 mm in keeping with current
guidelines [1, 8]. Replacement fibrosis was defined on a
binary scale as the presence of LGE reported by 2
physicians experienced in CMR interpretation for each
segment. All analyses were carried out blinded to the re-
sults of strain data.
Statistical analysis
Statistical analysis was performed using Stata 14
(StataCorp, 2015, College Station, TX). Continuous vari-
ables are expressed as means ± standard deviation (SD).
Categorical variables are expressed as N (%). Shapiro-Wilk
test was used to test normality then unpaired T test or
Mann Whitney U test used as appropriate. A mixed
effects model with random intercept for each person was
used to assess the association between Ecc-FT, Err-FT and
Ecc-SPAMM and segment thickness, native T1, ECV and
LGE. For each patient 16 segments with each parameter
were included in the model to include segments with vary-
ing degrees of phenotypic expression. This model was
used to account for the fact that segments from the same
patient may not behave independently. The association
between each strain parameter and segment thickness, na-
tive T1, ECV and LGE was tested using a two multivari-
able mixed effects model with random intercept adjusting
for all three independent variables. ECV is not statistically
independent from native T1 and therefore separate multi-
variable models were tested for each. Results are reported
as mean ± standard deviation. P < 0.05 was considered sta-
tistically significant.
Results
Fifty patients with HCM were recruited. Patient charac-
teristics are shown in Table 1. The distribution of hyper-
trophy was asymmetrical septal 36 (72%), concentric 5
(10%), mid cavity 4 (8%), apical 3 (6%) and isolated lat-
eral 2 (4%). An example of cine imaging, native T1, LGE
and ECV mapping from an identical slice of one patient
is shown in Fig. 1. Segment thickness, LGE and tissue
tagging could be analysed in all available segments.
Native T1 could be analysed in 781/800 segments
(median 1227 ms, interquartile range 1176-1271 ms)
and ECV in 756/800 segments (median 27.4%, interquar-
tile range 25.0-31.6%). Ecc-FT could not be analysed in
17/800 and Err-FT in 12/800 because of either artefact
or poor tracking of myocardial features.
Controls were 36.2 ± 11.6 years old and 22 (73%) were
male. From these controls the normal range for native
T1 was 1190 ± 24.7 ms and ECV 24.3 ± 2.6%. Therefore
segments with native T1 > 1239.4 ms and ECV > 29.5%
(+2 SD) were defined as abnormally elevated.
The presence of hypertrophy, LGE, raised native T1
and raised ECV were all associated with impairment of
all Ecc-FT, Err-FT and Ecc-SPAMM (P < 0.001 for all),
Table 2.
Mixed effects model with random intercept
On univariable analysis segment thickness, LGE, native T1
and ECV all had a significant association with Ecc-FT,
Err-FT and Ecc-SPAMM, Table 3. In multivariable
model 1 (segment thickness, LGE, ECV) only segment
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Fig. 1 CMR images from a patient with asymmetric septal HCM. a SSFP imaging showing gross septal hypertrophy (>15 mm). b Native T1 map
with colour scale ranging from 0 (purple) to 2000 ms (yellow). c Late gadolinium enhancement imaging showing a discrete area of replacement
fibrosis in inferoseptum (white arrow). d ECV map ranging from 0 (blue) to 100% (red) confirming replacement fibrosis (black arrow)
Table 1 Patient characteristics and findings
N 50 FH of HCM, n (%) 19 (38)
Male gender, n (%) 37 (74) CMR findings
Age, years 46.9 ± 11.7 LV EDV, ml/m2 78.7 ± 13.1
Height, cm 171.2 ± 9.0 LV EF, % 62.3 ± 5.9
Weight, kg 81.7 ± 14.6 LV Mass, g/m2 72.8 ± 26.3
Body mass index, kg/m2 27.7 ± 3.7 LAV, ml/m2 59.3 ± 13.5
Systolic blood pressure, mmHg 125.5 ± 17.6 LGE, n (%) 35 (70)
Diastolic blood pressure, mmHg 74.5 ± 12.5 Medications
Heart rate 60.6 ± 10.2 Beta blocker, n (%) 24 (48)
Echocardiography CC blocker, n (%) 8 (16)
Maximum wall thicknessa (mm) 19.3 ± 4.9 Disopyramide, n (%) 4 (8)
LVOT obstruction, n (%) 11 (22) Diuretic, n (%) 2 (4)
Resting LVOT gradient, mmHg 68.5 ± 40.0
CC calcium channel, EDV end diastolic volume indexed to body surface area, EF ejection fraction, FH family history, LAV left atrial volume indexed to body surface
area, LGE late gadolinium enhancement, LV left ventricle, LVOT left ventricular outflow tract
aIn 5 subjects with apical or localized lateral hypertrophy maximum wall thickness is taken from CMR
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thickness had a significant association with Ecc-FT
(Beta 1.317 (95% confidence interval (CI) 1.165;1.470),
P < 0.001). In multivariable model 2 (segment thickness,
LGE, native T1) both segment thickness (Beta 1.219 (95%
CI 1.070;1.368) P < 0.001) and native T1 (Beta 0.015 (95%
CI 0.008;0.022) P < 0.001) had significant association with
Ecc-FT.
In multivariable model 1 only segment thickness
had a significant association with Err-FT (Beta -3.532
(95% CI -4.011;-3.073), P < 0.001). In multivariable model 2
both segment thickness (Beta -3.193 (95% CI (-3.659;-2.726)
P < 0.001) and native T1 (Beta -0.053 (95% CI -0.075;-0.030)
P < 0.001) had significant association with Err-FT.
In multivariable model 1 both segment thickness (Beta
0.964 (95% CI 0.782;1.146), P < 0.001) and LGE (Beta
2.603 (95% CI 0.341;4.866), P = 0.024) had a significant
association with Ecc-SPAMM. In multivariable model 2
both segment thickness (Beta 0.0849 (95% CI 0.669;1.030)
P < 0.001) and native T1 (Beta 0.017 (95% CI 0.008;0.025)
P < 0.001) but not LGE had significant association with
Ecc-SPAMM.
Influence of genotype
10/50 patients had presence of a genetic mutation
known to cause HCM (MYBPC3 N = 7, MYH7 N = 4,
TNNI3 N = 1). There was a trend to higher native T1
overtly hypertrophied segments (>15 mm, N = 99) in geno-
type positive vs genotype negative patients, 1295.9 ± 65.1
vs 1272.3 ± 57.9 ms, P = 0.055. In the same segments there
was no significant difference in ECV in genotype positive
vs genotype negative patients, 37.1 ± 10.1 vs 34.8 ± 10.2%,
P = 0.23).
Discussion
Hypertrophic cardiomyopathy is characterised by both
cellular and extracellular pathological processes. With
CMR it is possible to assess both gross macroscopic
abnormalities, as reflected by segment thickness and
replacement fibrosis on LGE, as well both the cellular
and extracellular compartments at a microscopic level,
by assessing ECV and native T1.
We have demonstrated that segmental contractility after
correction for segment thickness has a significant associ-
ation with myocardial native T1 but not LGE or ECV.
ECV measurement assesses predominantly the extracellu-
lar compartment, whereas native T1 reflects the intracel-
lular water, iron and lipid content [22]. These findings
suggest that in HCM changes in the cellular structure and
function rather than extracellular expansion may mediate
impairment of myocardial contractility.
The cellular mechanisms that lead from mutation of
sarcomeric proteins to increased native T1 and impaired
contractile function remain to be established [5]. Native
T1 could help elucidate these mechanisms by identifying
the extent of cellular changes in patients with different
disease causing mutations. It also has the potential to be
a marker for monitoring disease progression, response
to clinical intervention and long-term prognosis.
Ecc-SPAMM is the best validated CMR method for
the assessment of strain [29, 30]. However it is ham-
pered by tag fading in diastole and the relatively coarse
tag separation of 7 mm may limit use in thinned regions
of myocardium. We have therefore also assessed strain
by FT which - although less well validated than tissue
tagging - overcomes the issues of tag fading and its
spatial resolution of 1.2x1.2 mm2 allows better assess-
ment of thinned regions of myocardium than is possible
with SPAMM. Both we and other groups have reported
good reproducibility of strain measured by this method
of FT. Reassuringly, both FT and SPAMM consistently
demonstrated a relationship between native T1 in two
orthogonal planes (circumferential and radial).
T1 mapping
Cellular changes that may be detected in HCM include
altered calcium cycling, impaired biomechanical stress
sensing and disturbed cardiac energy homeostasis [31]
and extracellular changes include myocyte disarray and
fibrosis [32, 33]. The assessment of both native T1 and
ECV by CMR offer the unique opportunity to assess
changes in both the cellular and extracellular compart-
ments non-invasively. ECV measured by T1 mapping
has shown to be elevated in HCM and has a strong cor-
relation with fibrosis measured histologically [19, 34].
There is already clear evidence that in HCM both na-
tive T1 [23, 35] and ECV [19, 36] are elevated. This in-
crease can even be detected in those with sarcomeric
mutations but without overt hypertrophy [24]. We have
observed that for all three measures of regional strain
native T1 but not ECV was associated with contractile
function suggesting that changes in cellular rather than
extracellular tissue characteristics contribute predomin-
antly to loss of contractile function in HCM. An alterna-
tive explanation is that native T1 is a stronger marker of
fibrosis than ECV. However this seems less likely given
that native T1 reflects intracellular as well as extracellu-
lar signal and studies have demonstrated that native T1
has a much weaker association with histological mea-
sures of extracellular fibrosis than ECV [37, 38].
The major shortcoming of native T1 is that it varies
significantly between field strengths, scanner vendor and
technique used to measure it [39] and in clinical practice
requires validation for the specific pulse sequence and
field strength used [18]. We have previously reported ex-
cellent reproducibility in both phantom and human
studies of the pulse sequence used in this study [40].
However native T1 has merits that would support its use
in this clinical application. Unlike ECV its measurement
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does not require intravenous cannulation, administration
of contrast, or a blood sample to measure haematocrit.
Late gadolinium enhancement
We have reported, from multivariable model 2, that
native T1 but not LGE has a significant association with
impairment of regional function. LGE, like ECV, is
directly influenced by the extent of extracellular fibrosis
with a strong linear correlation between the extent of
LGE within a particular segment and the amount of
collagen measured histologically [14].
We identified that LGE, even after correction for
segment thickness, had a significant association with
Ecc-SPAMM (multivariable model 1) in keeping with pre-
vious studies which did not include T1 mapping [6, 7].
However, when native T1 was included (multivariable
model 2) the association was no longer significant suggest-
ing again that changes in cellular structure are more deter-
minant in regional contractility.
In HCM, there is a strong correlation between extent
of LGE and ECV expansion [36] although the associ-
ation between native T1 and LGE is much weaker [25].
Increased native T1 can be detected in regions without
LGE [35, 41] and is therefore a good discriminator be-
tween healthy and diseased myocardium [23]. The fact
that native T1 influences contractile function but LGE
does not adds to the existing literature in demonstrating
that it is able to measure cellular changes that we have
previously been unable to quantify.
Segment thickness
We have also reported that segmental strain is strongly
associated with segment thickness. These findings cor-
roborate previous studies that have shown a relationship
between degree of hypertrophy and presence of LGE
and strain measured by speckle tracking echocar-
diography [6, 7] and feature tracking by CMR [42].
Dhillon et al. measured longitudinal strain by feature
tracking echocardiography in subjects with HCM under-
going surgical myomectomy, also reporting histological
findings and in vitro contractility of the surgically ex-
cised myocardium. They found that the degree of histo-
logical fibrosis correlated with both strain measured by
echocardiography and in vitro [43]. However strain was
measured in segments with severe hypertrophy causing
LVOT obstruction and more than half of the specimens
studied displayed small intramural coronary arteriole
dysplasia which is known to correspond strongly with
focal LGE detected by CMR [44]. Therefore the subjects
studied were at the severe end of the hypertrophic
spectrum and not directly comparable with subjects and
segments in the present study with a wide range of
phenotypic presentations.
Limitations
The patients studied all had an established HCM with a
diagnosis made according to current guidelines [1, 8].
Our findings cannot therefore be extrapolated to those
without overt expression of HCM. The correlation of
both native T1 and ECV with cellular and extracellular
changes has not been tested histologically in the study
however but has been done in previous studies [19, 34].
We have only measured strain from short axis mea-
surements specifically because the strength of the seg-
mental analysis that we have carried out is based on the
fact that T1 maps, SSFP cines and LGE acquisitions can
all be carried out in the identical short axis plane. Com-
paring strain from long axis cines to ECV from short
axis maps would add an unacceptable degree of error.
Conclusions
Regional strain impairment measured by feature tracking
and SPAMM is predominantly associated with the de-
gree of hypertrophy and native T1, but not extracellular
fibrosis (LGE or ECV). These findings suggest that im-
pairment of contractility in HCM may be mediated by
mechanisms other than extracellular expansion that may
include cellular changes in structure and function. The
cellular mechanisms leading to increased native T1 and
its prognostic significance remain to be established.
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